Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMPDW6T)

Drug Name
Epirubicin Drug Info
Synonyms
Ellence; Epiadriamycin; Epidoxorubicin; Epirubicina; Epirubicine; Epirubicinum; Pidorubicin; Pidorubicina; Pidorubicine; Pidorubicinum; Ridorubicin; Epirubicina [Spanish]; Epirubicine [French]; Epirubicinum [Latin]; Pharmorubicin Pfs; IMI 28; WP 697; Ebewe (TN); Ellence (TN); Epi-DX; Epirubicin (INN); Epirubicin (TN); Epirubicin [INN:BAN]; Epirubicina [INN-Spanish]; Epirubicine [INN-French]; Epirubicinum [INN-Latin]; Farmorubicin (TN); Pharmorubicin (TN); Pidorubicina [INN-Spanish]; Pidorubicine [INN-French]; Pidorubicinum [INN-Latin]; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione; 4'-Epi-DXR; 4'-Epiadriamycin; 4'-epi-DX; 4'-epi-Doxorubicin; 4'-epidoxorubicin; 4-Epidoxorubicin
Therapeutic ClassAnticancer Agents
Cross-matching ID
PubChem CID
41867
ChEBI ID
CHEMBL417
CAS Number
CAS 56420-45-2
TTD Drug ID
D0C9XJ
VARIDT Drug ID
DR00170
INTEDE Drug ID
DR0591

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Graft-versus-host disease 2.47 0.00e+0 32/42 (76.19%) FAS;HLA-C;HLA-B;...
Type I diabetes mellitus 2.42 0.00e+0 38/43 (88.37%) CPE;FAS;HLA-C;...
Allograft rejection 2.40 0.00e+0 32/38 (84.21%) FAS;HLA-C;HLA-B;...
Viral myocarditis 2.33 0.00e+0 53/60 (88.33%) HLA-C;HLA-B;HLA-F;...
Epstein-Barr virus infection 2.23 0.00e+0 189/202 (93.56%) CDKN1A;DDB2;ISG15;...
Autoimmune thyroid disease 2.21 0.00e+0 46/53 (86.79%) FAS;HLA-C;HLA-B;...
Lysosome 2.13 0.00e+0 115/128 (89.84%) LAMP3;CTSV;CTSL;...
p53 signaling pathway 2.11 0.00e+0 63/73 (86.3%) CDKN1A;DDB2;RRM2;...
Inflammatory bowel disease 2.06 0.00e+0 58/65 (89.23%) MAF;STAT1;IL1B;...
Other glycan degradation 1.96 3.97e-3 13/18 (72.22%) HEXA;MAN2B2;FUCA1;...
Phagosome 1.95 3.60e-3 118/152 (77.63%) TAP1;HLA-C;HLA-B;...
Herpes simplex virus 1 infection 1.90 5.51e-3 165/498 (33.13%) TAP1;FAS;OAS1;...
Cytokine-cytokine receptor interaction 1.89 6.10e-3 246/295 (83.39%) CXCL10;FAS;CCL5;...
Antigen processing and presentation 1.89 5.66e-3 60/78 (76.92%) TAP1;HLA-C;HLA-B;...
Dilated cardiomyopathy 1.88 5.29e-3 86/96 (89.58%) ITGB5;TPM2;TNNC1;...
Viral protein interaction with cytokine and cytokine re... 1.88 4.96e-3 84/100 (84%) CXCL10;CCL5;CXCL13;...
Influenza A 1.88 5.44e-3 156/172 (90.7%) CXCL10;FAS;OAS1;...
Cardiac muscle contraction 1.85 7.34e-3 64/87 (73.56%) TPM2;TNNC1;ATP2A2;...
Glioma 1.85 6.96e-3 67/75 (89.33%) CDKN1A;DDB2;TGFA;...
Rheumatoid arthritis 1.84 9.25e-3 78/93 (83.87%) CCL5;CTSL;IL1B;...
Measles 1.83 8.81e-3 133/139 (95.68%) FAS;OAS1;MX1;...
Mismatch repair 1.82 9.01e-3 22/23 (95.65%) LIG1;MLH1;POLD4;...
Glycosaminoglycan degradation 1.82 9.20e-3 19/19 (100%) HEXA;GALNS;HEXB;...
Pancreatic cancer 1.81 9.36e-3 75/76 (98.68%) CDKN1A;DDB2;TGFA;...
Natural killer cell mediated cytotoxicity 1.79 1.06e-2 99/131 (75.57%) FAS;HLA-C;HLA-B;...
Hypertrophic cardiomyopathy 1.79 1.02e-2 81/90 (90%) ITGB5;TPM2;TNNC1;...
Various types of N-glycan biosynthesis 1.78 1.13e-2 26/39 (66.67%) RPN2;HEXA;DDOST;...
Kaposi sarcoma-associated herpesvirus infection 1.78 1.13e-2 172/193 (89.12%) CDKN1A;LEF1;FAS;...
Non-small cell lung cancer 1.77 1.09e-2 70/72 (97.22%) CDKN1A;DDB2;TGFA;...
Malaria 1.77 1.10e-2 44/50 (88%) IL1B;KLRB1;ICAM1;...
Aminoacyl-tRNA biosynthesis -1.70 3.73e-2 15/66 (22.73%) GATC;LARS2;WARS2;...
Terpenoid backbone biosynthesis -1.71 4.36e-2 18/22 (81.82%) FDPS;ICMT;IDI1;...
Ribosome -1.85 9.78e-3 113/158 (71.52%) RPL12;RPL24;RPL28;...
Porphyrin and chlorophyll metabolism -1.92 1.86e-3 23/43 (53.49%) UGT2B15;BLVRB;HMOX2;...
Spliceosome -2.10 0.00e+0 101/150 (67.33%) PRPF38B;SMNDC1;PRPF8;...
Ribosome biogenesis in eukaryotes -2.25 0.00e+0 52/108 (48.15%) GNL3;HEATR1;NVL;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 0.12uM - 1.11uM 24H
TC-32 CVCL_7141 Homo sapiens 0.12uM 24H
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.12uM - 10uM 6H, 24H, 48H
Brain
Glioblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-251 MG CVCL_0021 Homo sapiens 0.12uM - 10uM 24H
YH-13 CVCL_1800 Homo sapiens 0.12uM - 10uM 24H
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 0.12uM - 1.11uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-468 CVCL_0419 Homo sapiens 0.12uM - 1.11uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BT-474 CVCL_0179 Homo sapiens 0.12uM - 10uM 24H
T-47D CVCL_0553 Homo sapiens 0.12uM - 10uM 24H
ZR-75-1 CVCL_0588 Homo sapiens 0.12uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GP2d CVCL_1234 Homo sapiens 0.12uM - 10uM 24H
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
SNU-407 CVCL_5004 Homo sapiens 0.12uM - 10uM 24H
Embryonic stem cell
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WA09 (H9) Derived CVCL_9773 (WA09) Homo sapiens 0.12uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 0.12uM - 10uM 24H
HEC-151 CVCL_2927 Homo sapiens 0.12uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 0.12uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 0.12uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 0.12uM - 10uM 24H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
CJM CVCL_U797 Homo sapiens 0.12uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
1HAEo- CVCL_0128 Homo sapiens 10uM 24H
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
NL20 CVCL_0461 Homo sapiens 10uM 24H
Renal cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
RCC10RGB CVCL_1656 Homo sapiens 0.12uM - 10uM 24H
Rhabdoid tumor
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
G-401 CVCL_0270 Homo sapiens 0.12uM - 1.11uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 0.12uM - 10uM 24H
JHH-7 CVCL_1322 Homo sapiens 0.12uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
NCI-H1437 CVCL_1472 Homo sapiens 0.12uM - 10uM 24H
NCI-H1573 CVCL_1483 Homo sapiens 0.12uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 0.12uM - 1.11uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 0.12uM - 10uM 24H
HCC1588 CVCL_1263 Homo sapiens 0.12uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 0.12uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
NCI-H2110 CVCL_1529 Homo sapiens 0.12uM 24H
NCI-H2172 CVCL_1534 Homo sapiens 0.12uM - 1.11uM 24H
Normal (Fibroblast)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HFL1 CVCL_4295 Homo sapiens 10uM 24H
IMR-90 CVCL_0347 Homo sapiens 10uM 24H
WI-38 CVCL_0579 Homo sapiens 10uM 24H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H841 CVCL_1595 Homo sapiens 0.12uM - 1.11uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 0.12uM - 10uM 24H
Oral cavity
Oral squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BICR 6 CVCL_1086 Homo sapiens 0.12uM - 10uM 24H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVK18 CVCL_1629 Homo sapiens 0.12uM - 1.11uM 24H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ES-2 CVCL_3509 Homo sapiens 0.12uM - 10uM 24H
OVTOKO CVCL_3114 Homo sapiens 0.12uM - 10uM 24H
Ovarian cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OAW 28 CVCL_1611 Homo sapiens 0.12uM - 10uM 24H
OC 316 CVCL_1615 Homo sapiens 0.12uM - 10uM 24H
Ovarian endometrioid carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TOV-112D CVCL_3612 Homo sapiens 0.12uM 24H
Ovarian granulosa cell tumor
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV434 CVCL_2010 Homo sapiens 0.12uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.04uM - 3.33uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 3.33uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 0.12uM - 10uM 24H
LNCaP clone FGC CVCL_1379 Homo sapiens 0.12uM - 10uM 24H
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
IGR-37 CVCL_1303 Homo sapiens 0.12uM - 1.11uM 24H
Mel-HO CVCL_1402 Homo sapiens 0.12uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 0.12uM - 1.11uM 24H
SK-MEL-3 CVCL_0525 Homo sapiens 0.12uM - 10uM 24H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 0.12uM - 10uM 24H
MKN45 CVCL_0434 Homo sapiens 0.12uM - 10uM 24H
Gastric carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
IM95 CVCL_1305 Homo sapiens 0.12uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 0.12uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 0.12uM - 1.11uM 24H